

PHARMACEUTICAL LAW & INDUSTRY REPORT & REG; INDEX-SUMMARY

— Vol. 7, Nos. 1-26 pp. 1-758
— Jan. 2-Jun. 26, 2009

A

ABBREVIATED NEW DRUG APPLICATIONS (ANDAs)

Bioequivalence

—Data submission, FDA issues draft guidance, 471
—Product specific studies, FDA issues final recommendations, 685
—Studies, FDA issues rule, 98
Clobel patent infringement alleged (N.D. Tex.), 63
Generic drugs
—Allegra-D maker tries to block generic (D.N.J.), 119
—Cardene, generic ANDA challenged (D.N.J.), 401
—Doryx generic ANDAs challenged as infringement, 14
—Fortamet, generic ANDA challenged (D. Del.), 97
—Truvada V drug ANDA infringes patent (S.D.N.Y.), 10
Lotrel low-dose ANDA challenged as infringement (D.N.J.), 13; dismissed, 201
Pataday. *See* PATADAY
Withdrawals not due to safety or effectiveness, FDA says, 19; 19 drugs withdrawn, 715

ACCREDITATION AND CERTIFICATION

Pfizer study subject protection program accredited, 417

ACCUTANE

Acne drug blamed for inflammatory bowel disease, new trial ordered (N.J. Super. Ct.), 313
Failure-to-warn of suicide risk, maker wins summary judgment (11th Cir.), 705

ACTIMMUNE

Class action over off-label use marketing dismissed (N.D. Cal.), 583
Indictment of CEO over off-label use promotion upheld (N.D. Cal.), 675

ACTONEL

Bone-blocking drug, generic version challenged (D. Del.), 150
Osteoporosis drug patent upheld against generic maker (Fed. Cir.), 581

ACULAR

Eye inflammation treatment patent upheld (U.S., rev den), 117

ADVERSE EFFECTS

Mixing prescription and OTC drugs, adverse reactions in seniors possible, 21

ADVERSE EVENTS

Canada, reporting changes considered, 721
Genetic basis for certain events, FDA releases data, 182
Raptiva, FDA issues advisory, 233
Toll-free number on medication guides, FDA issues guidance, 686

ADVERTISING

Avodart, FDA says TV ad is misleading, 271
Brazil revises rules, 27
Depakote, FDA tells maker to pull misleading materials, 159
GSK plans \$400M charge, federal probe cited, 160
HRT claims, jurisdiction lacking over ad firms with insufficient W.Va. contacts (E.D. Ark.), 367
Humira ad broadens approved indication and minimizes risks, FDA says, 21
Nexium, false advertising class action remanded (3rd Cir.), 587
Protonix, generic advertising challenged (E.D. Mich.), 554

Risk information

—Draft guidance issued by FDA, 618
—Lacking from many Internet ads, 413
Ultram ER web video called misleading by FDA, 623
Velcade maker accused of overstating efficacy, 746
Yaz maker to submit TV ads to FDA, 189

AFINITOR

Approved for kidney cancer, 383

AIDS AND HIV

IDX889 licensing, In Brief, 191
IQP-0410, In Brief, 49
Kaletra, price cut in Mexico, 387
Specialist firm planned, In Brief, 486

ALABAMA

Medicaid
—E-prescribing system announced, 648
—Pricing
—5 firms settle with state (Ala. Cir. Ct.), 40
—Jury awards \$78.4M (Ala. Cir. Ct.), 227
—More firms settle (Ala. Cir. Ct.), 610

ALDARA

Skin cancer cream blamed for severe symptoms, claim time-barred (D. Utah), 257

ALLEGRA-D

Allergy drug maker tries to block generic (D.N.J.), 119

ANALYSIS & PERSPECTIVE

De-identified health information and state regulation, 422
Federal preemption in drug and device suits, 106
Foreign Corrupt Practices Act compliance, 215
Patents
—Reversing patent settlements, 749
—Risk evaluation and mitigation strategy patents, 28
Phenergan failure to warn claim, 353; effect on preemption defense, 658
Trademarks, proving use, 52

ANDAs *See* ABBREVIATED NEW DRUG APPLICATIONS (ANDAs)

ANDROGEL

Class actions seek to recoup charges paid due to collusion between brand name and generic firms (C.D. Cal.), 174; transferred to Ga. federal court, 435; N.J. suits transferred (D.N.J.), 670
Testosterone replacement drug, FTC accuses generic and brand name makers colluding to delay (C.D. Cal.), 145

ANTI-KICKBACK LAWS

UN Oil for Food Program, Danish firm settles charges (D.D.C.), 558

ANTIBIOTICS

Cephem compound double patent challenge, summary judgment vacated (Fed. Cir.), 433
Doryx. *See* DORYX
Flucloxacillin associated with liver damage, 652
HGS and Morphotek, In Brief, 386
Plectasin NZ2114, In Brief, 25
Trovan maker accused of violating international norms (2nd Cir.), 147

ANTIDEPRESSANTS

Consolidation of product liability claims denied (D. Mo.), 639
Failure-to-warn of suicide risk, preemption ruling remanded (U.S.), 280; vacated and remanded (3rd Cir.), 497; briefs filed, 498
Lexapro approved for adolescents, 350
Paxil. *See* PAXIL

ANTITRUST

AndroGel, class actions seek to recoup charges paid

due to collusion between brand name and generic firms (C.D. Cal.), 174; transferred to Ga. federal court, 435; N.J. suits transferred (D.N.J.), 670
Apotex counterclaims against Daiichi dismissed (D.N.J.), 636
BMS to settle with states over court order violations, 12
Cipro settlement challenged (U.S., rev den), 730
CVS Caremark merger, FTC probe sought, 565; pharmacists group alleges monopoly, 565
False statements, former exec ordered to write book about case (D.D.C.), 679
Hytrin monopoly claim remanded (9th Cir.), 91
K-Dur purchasers class certified (D.N.J.), 38; special master recommends dropping, 175
Leibowitz as FTC chair, more scrutiny predicted for drug industry, 261
Nifedipine direct purchasers class action certified (D.C. Cir.), 229
Ovcon settlement reached (D.D.C.), 12
Plavix suit, former executive pleads guilty to false statements (D.D.C.), 401
Reverse payment deals
—Position of Obama administration sought, 476
—Targeted by FTC, 372
Tricor, consumer suit over generic delay, settlement approved (D. Del.), 500
Wellbutrin, direct purchaser antitrust suit may proceed (E.D. Pa.), 308

APPLICATIONS

Acetavance, In Brief, 596
Acurox, In Brief, 51; 272; 747
Afresa, In Brief, 324; new application, In Brief, 595
Apirin-ulcer drug combo, In Brief, 541
AR-12, In Brief, 570
AR-42, In Brief, 324
Arzerra, In Brief, 164; called safe and effective by FDA panel, 649; review extended, In Brief, 720
Bepreve, In Brief, 105
Botox, In Brief, 626
Cefazolin, In Brief, 655
Certrid, In Brief, 692
Cervarix, In Brief, 385
Cimzia, FDA wants more data, 46
Cinryze. *See* CINRYZE
Colitis drug, FDA wants more data, 46
Cymbalta, In Brief, 655
Denosumab, In Brief, 24
Diabetes treatment, FDA to apply guidance, 295
Durezol, In Brief, 324
DX-88, In Brief, 385
Erbix, In Brief, 134
Exenatide, In Brief, 541
Fampridine-SR, In Brief, 385; 571
Fenretinide, In Brief, 450
Flutiform, In Brief, 627; FDA may need more data, In Brief, 691
Ganciclovir ophthalmic gel, In Brief, 134
Genasense, In Brief, 297
GGTI-2418, In Brief, 192; 271
Imitrex, In Brief, 213
Intence, In Brief, 192
Intermezzo, In Brief, 719
Invega, In Brief, 191
Isolagen Therapy, In Brief, 298
LiquiXR, In Brief, 570
Loramyc, In Brief, 720
Lucassin, In Brief, 719
Lumizyme, FDA seeks more information, 270
MonoSol XR, In Brief, 451
Nexium, In Brief, 25
NGX-4019, In Brief, 25
Nonsteroidal anti-inflammatory drug, 418
Ondansetron ODFS, In Brief, 691
Onglyza timeline extended, 513
Ongrin, In Brief, 212; application accepted, 486
Pegloticase, In Brief, 50; 51
Pixantrone, In Brief, 134; rolling submission, In Brief, 451; priority review sought, In Brief, 747

APPLICATIONS —Contd.

PN 400, In Brief, 596
PolyHeme not approved, In Brief, 542
Reloxin, In Brief, 78
Restanza called safe, but not effective by FDA panel, 649
Rexin-G, In Brief, 720
Rezonix, In Brief, 747
Risperdal, In Brief, 213
Rituxan, In Brief, 595
ROX-888, In Brief, 192
Saphris, In Brief, 105; 238
Seroquel XR, In Brief, 24
Stelara, In Brief, 626
Sunitinib, In Brief, 595
Surfaxin, FDA wants more data, 477
Symbicort, In Brief, 418
Tarceva, In Brief, 352
Tykerb, In Brief, 384
Tyvaso, In Brief, 324; 515
Ustekinumab, In Brief, 25
Xiaflex, In Brief, 515
XP12B, In Brief, 419
Zegerid, In Brief, 164
Zenpep, In Brief, 747
Zogenix, In Brief, 212
Zyprexa, In Brief, 78

APPROVALS

ACTOplus met, In Brief, 569
Adecira, In Brief, 626
Apidra SoloSTAR, In Brief, 272
Atryn approved by FDA, 190
Avastin, FDA panel favors approval for brain cancer, 381; approved, 540
Average approval time down at FDA, development time up, 74
Axert, In Brief, 692
Azor, In Brief, 570
Besivance approved, 651
Cimzia, In Brief, 596
CIP-Tramadol ER, In Brief, 212
Citizen petitions, FDA issues draft guide, 122
Coartem tablets approved for malaria infections, 416
Creon, In Brief, 541
Degarelix approved, 22
DX-88, FDA panel favors approval, 188
Fanapt approved for adult schizophrenia with warning, 539
Gelnique, In Brief, 134
Generics. *See* GENERIC DRUGS
Gleevec approved, 23
Ibuprofen injectable dosage approved by FDA, 717
Ilaris, In Brief, 748
Kapidex, In Brief, 164
Krystexxa, In Brief, 719
Lamictal XR, In Brief, 656
Lexapro approved for adolescents, 350
Multaq, FDA panel favors approval, 350
Nexterone, In Brief, 50
Onglyza, FDA panel favors approval, 414
Prasugrel, FDA panel favors approval, 159; consumer group opposes, 649
Provenge, politically-motivated delay in approval alleged, dismissal affirmed (U.S., rev den), 61
Reclast, In Brief, 656
RiaSTAP approved for bleeding in patients with congenital fibrinogen deficiency, 102
Rivaroxaban gets favorable review from FDA panel, 351; gets complete response letter, 650
Ryzolt, In Brief, 51
Sabril cleared by FDA panel, 73
Samsca, In Brief, 627
Sanvar, In Brief, 627
Savella, In Brief, 105
Silenor application rejected by FDA, 446
Simponi for arthritis, 513
Symbicort, In Brief, 272
Symbyax, In Brief, 352
Tygacil, In Brief, 352

Uloric, In Brief, 212
Vancomycin, In Brief, 570
Vectical, In Brief, 163
Zingo, In Brief, 77
Zipsor, In Brief, 748
Zolpimist, In Brief, 24
Zyprexa, In Brief, 352

ARANESP

Anemia drug off-label use class action dismissed (C.D. Cal.), 730
Illegal marketing alleged (D. Mass.), 255

ARBITRATION

Remicide distribution agreement, arbitration sought, 622

ARZERRA

Leukemia drug, In Brief, 164; called safe and effective by FDA panel, 649

ATRYN

Anticoagulant approved by FDA, 190

ATTORNEYS

Falsified drug paperwork (D.N.H.), In Brief, 617
Fen-phen settlement, attorneys convicted of bilking plaintiffs (E.D. Ky.), 467

AVASTIN

Brain cancer treatment, FDA panel favors approval, 381; approved, 540
CalPERS approves for ovarian cancer, 296

AVODART

Prostate treatment, FDA says TV ad is misleading, 271

AZOPT

Eye drug maker alleges infringement (E.D. Tex.), 119

B

BCBS *See* BLUE CROSS AND BLUE SHIELD PLANS (BCBS)

BESIVANCE

Bacterial conjunctivitis drug approved, 651

BEXTRA

Arthritis drug trade secrets, Pfizer must pay \$38M to research firm (Cal. Super.), 11
Consumer fraud and injury class action settlement gets preliminary approval (N.D. Cal.), 339
Off-label marketing, ex-sales manager pleads guilty (D. Mass.), 370; sentenced, 736

BIOGENERICS

Approval pathway sought by firm, 186; AARP seeks, 290; would cut costs, FTC says, 681; CareFirst supports, 690; MedPAC reports, 710; House debate to continue, 713
Cost containment and biogenerics examined by CBO, 16
Hatch (R-Utah) pushes, 288
Legal outlook 2009, 79
License revocations, FDA issues notification rule, 532
Regulatory outlook 2009, 80
Waxman (D-Cal) pushes, 686

BIOLOGICS

Approval pathway for generics sought, 186
Arzerra, In Brief, 720
Atryn approved by FDA, 190
Cimzia. *See* CIMZIA
Cinryze. *See* CINRYZE
Consensus sought on generic biologics, 235
Denosumab, In Brief, 212
Erbitux. *See* ERBITUX
GSK and Dynavax, In Brief, 26
Merck follow-on platform, In Brief, 213

Plant shut down, 718
PolyHeme maker shuts down, 594

BIRTH CONTROL *See* CONTRACEPTION

BLOOD PRODUCTS

Taiwanese hemophiliacs claims against concentrate makers time-barred (N.D. Ill.), 466

BLUE CROSS AND BLUE SHIELD PLANS (BCBS)

Generic drugs, community-based programs expanding use, 450

BRAZIL

Advertising rules revised, 27
Domestic equivalents to replace drug imports, 487
Patents, pipeline law challenged, 597
Price hikes authorized, 387

BUDGET, U.S. *See specific agencies and departments*

FY2010. *See* LEGISLATION, FEDERAL, SConRes 13

C

CABILLY II

Antibody production patent, PTO confirms claims of validity, 270

CALIFORNIA

Medi-Cal cuts challenged by pharmacists (C.D. Cal.), 151; cuts enjoined, 256; hospital and pharmacy reimbursement cuts blocked (9th Cir.), 404
Overtime for drug firm sales reps, guidance sought from Cal. court (9th Cir.), 555
Pricing, counties denied class certification in suit against drug firms (N.D. Cal.), 611
State and local government employees
—Avastin, CalPERS approves for ovarian cancer, 296
—E-prescriptions, CalPERS plans pilot project, 348

CAMPATH

MS drug, Genzyme buys rights, 384

CANADA

Adverse event reporting changes considered, 721

CANCER

Afinitor approved for kidney cancer, 383
Antitumoral agent, In Brief, 191
AR-12, In Brief, 570
AR-42, In Brief, 324
Arzerra called safe and effective by FDA panel, 649
Avastin. *See* AVASTIN
Cervarix, In Brief, 385
Combination drugs, In Brief, 571; 656
Debio 0928, In Brief, 748
DI-Leu 16-IL2 license, In Brief, 323
DTS-108, In Brief, 25
Elesclomol, In Brief, 720
Eloxatin, proposed generics no infringement (D.N.J.), 732
Erbitux. *See* ERBITUX
Gleevec approved, 23
GSK and Oxford collaboration, In Brief, 595
Liraglutide cancer risk disputed, 414
MDV3100, In Brief, 324
MDX-1203, In Brief, 164
MDX-1338, In Brief, 626
Medicare contractor to cover off-label use for ovarian cancer treatment, 471
MORAb-004, In Brief, 691
New drugs, 861 in development, 383
(131)I-CLR1404, In Brief, 272
Paclical, In Brief, 451
PLK-1, In Brief, 570
Rexin-G, In Brief, 720
Sunitinib, In Brief, 595

CANCER —Contd.

Treanda patients, skin reaction reported, 513
 Xeloda, generic challenged (D.N.J.), 438

CARDENE

Cardiac drug, generic ANDA challenged (D.N.J.), 401

CARVEDILOL

Congestive heart failure treatment, infringement claim settled (D.N.J.), 587

CELEBREX

Consumer fraud and injury class action settlement gets preliminary approval (N.D. Cal.), 339

CELEXA

Antidepressant competing patents, two claims invalidated by prior art (S.D.N.Y.), 673

CELLCEPT

Miscarriage risk, FDA requires medication guide with prescriptions, 210

CHANTIX

Smoking cessation product wrongful death suit, breach of warranty claim may proceed (S.D. Ind.), 178

CHILDREN'S HEALTH CARE

ADHD drugs tied to cardiac deaths, FDA reports, 714
 Identifying knowledge gaps on drugs and children, NIH plans program, 443
 Off-label use of pediatric products, Special Report, 572

CIMZIA

Arthritis drug, FDA wants more data before approval, 46
 Licensing, In Brief, 191

CINRYZE

Angioedema treatment gets priority review, 163; FDA seeks more data, 690

CIPRO

Cipro settlement challenged (U.S., rev den), 730

CLARINEX

Allergy drug patent suit settled (D.N.J.), 437

CLASS ACTIONS

AndroGel, suits seek to recoup charges paid due to collusion between brand name and generic firms (C.D. Cal.), 174; transferred to Ga. federal court, 435
 Bextra/Celebrex consumer fraud and injury class action settlement gets preliminary approval (N.D. Cal.), 339
 Cal. counties denied class certification in pricing suit against drug firms (N.D. Cal.), 611
 K-Dur purchasers class certified (D.N.J.), 38; special master recommends dropping, 175
 Merck employees class action over allegedly artificially inflated stock certified (D.N.J.), 204
 Neurotonin. *See* NEUROTONIN
 Nexium, false advertising class action remanded (3rd Cir.), 587
 Nifedipine direct purchasers antitrust class action certified (D.C. Cir.), 229
 Off-label use. *See generally* OFF-LABEL USE
 Prilosec, maker accused of failure to warn of food poisoning risk (S.D. Ohio), 680
 Securities. *See* SECURITIES
 Vioxx. *See* VIOXX
 Viread maker accused of misrepresenting sales (N.D. Cal.), 679
 Wellbutrin, generic makers accused of making inferior product (Cal. Super. Ct.), 706
 Zyprexa overpayments, class certification for third party payers granted (2nd Cir.), 152

CLINICAL TRIALS

Antitumoral agent, In Brief, 191
 ATPace, In Brief, 212; design approved, In Brief, 655
 Billing audit and monitoring conference planned by BNA, In Brief, 76
 BNA plans conference, In Brief, 48
 CD-NP, In Brief, 596
 Certification, FDA issues final guidance, 124
 CM-AT, In Brief, 352
 CollaRx Bupivacaine Implant clinical trial enjoined (E.D. Pa.), 149
 Contract research organizations addressed at BNA audiocconference, 477
 DP-b99, In Brief, 692
 Esreboxetine, In Brief, 237
 Fibromyalgia, In Brief, 237
 Financial disclosures, HHS IG criticizes FDA oversight, 66
 Investigator may be criminally liable for not following FDA reporting requirements (5th Cir.), 175
 IQP-0410, In Brief, 49
 MDV3100, In Brief, 324
 MDX-1203, In Brief, 164
 MDX-1338, In Brief, 626
 Minn. psychiatric clinical trial limits, bill signed, 593
 MORAb-004, In Brief, 691
 MoxDuo IR, In Brief, 239
 (131)I-CLR1404, In Brief, 272
 Payments to providers and institutions, GSK to disclosure, 382
 PD 332,334, In Brief, 237
 PLK-1, In Brief, 570
 Registries use up, reporting requirements of journals and agencies cited, 410
 Stem cell ALS trial, In Brief, 26
 Syncria, In Brief, 212
 VIA-2291, In Brief, 719

CLOBEL

Psoriasis drug patent infringement alleged (N.D. Tex.), 63

COARTEM

Approved for malaria infections, 416

COLLARX BUPIVACAINE IMPLANT

Pain relief, combination drug clinical trial enjoined (E.D. Pa.), 149

COLLEGES AND UNIVERSITIES

Ferris State Univ. sued by labor coalition, drug plan data sought (Mich. Cir. Ct.), 283
 Grassley (R-Iowa) wants conflict of interest disclosures by med schools, 741
 Harvard Medical School to revise conflicts of interest policy, 161
 Stanford med school to post MD-industry ties, 416
 Univ. of Iowa proposes new conflicts of interest policy, 160

COMBIGAN

Glaucoma drug, generic challenged (E.D. Tex.), 438

COMBINATION DRUGS

Anticancer combo, In Brief, 656
 Cancer, In Brief, 571
 CollaRx Bupivacaine Implant clinical trial enjoined (E.D. Pa.), 149
 Communication between FDA and makers urged, 409
 Diet drug blamed for death (E.D. Pa.), 438
 Guidance on clinical trials sought by industry, 651
 Injection devices, FDA issues draft guidance, 506
 LTX-315 and GV1001, In Brief, 747

COMPARATIVE EFFECTIVENESS

AHRQ use of funds at issue, 411
 Baucus (D-Mont) and Grassley (R-Iowa) offer policy options, 503; Baucus say no rationing of care, 684
 Coelho to lead research group, 322
 Commonwealth Fund supports research, 211

Discussed at conference, 712
 Examined by CBO, 16
 GOP senators drafting proposal, 711
 Health reform with comparative effectiveness will give providers more control over treatment decision, report says, 449
 HELP panel releases draft Senate bill, 683; markup, 739
 Innovation as focus urged for lawmakers, 483
 "Listening session," federal panel hears concerns, 441; panel holds second session, 591; patent-focused research urged, 684
 Medicare, use of comparative effectiveness research urged, 104
 Patient-centered solutions pushed, 75
 Savings and improved outcomes called key, 103; systems in other nations studied, 625
 Stimulus bill. *See* LEGISLATION, FEDERAL, HR 1, S 1

CONCERTA

ADHD drug, generic no infringement (D. Del.), 364

CONFERENCES AND MEETINGS

American Bar Ass'n Antitrust Law Section, 372
 American Intellectual Property Law Ass'n, Mid-Winter Institute, 186
 BIO 2009, 622; 654
 BNA, "Planning for a Post *Levine* World: Implications and Strategies for Manufacturers, U.S. Consumers and the Courts," 564
 Center for Business Intelligence, 745
 Food and Drug Law Institute, Annual Conf., 504
 Generic Pharmaceutical Ass'n annual meeting, 235
 Natl. Pharmaceutical Council, Entering a New Era of Evidence, 712
 U.S. Chamber of Commerce, 103; 104

CONFLICTS OF INTEREST

Clinical trials, payments to providers and institutions, GSK to disclosure, 382
 Gifts to MDs. *See* PHYSICIANS
 Grassley (R-Iowa) wants disclosures by med schools, 741
 Massachusetts
 —Fees for covered firms due Jul. 1, 648
 —Hospital network to limit interaction with industry, 441
 Medicare compendia, conflicts of interest seen as inherent, 625
 Physicians. *See* PHYSICIANS
 Univ. of Iowa proposes new policy, 160

CONGRESS, U.S.

Ed. Note: This heading is used for administrative actions only. For coverage of legislation by bill number, see LEGISLATION, FEDERAL. For information on measures not yet assigned bill numbers see specific subject headings.
 Hill Watch, In Brief, 452

CONNECTICUT

Gifts to MD, ban urged, 293

CONTAN

Parkinson's drug infringement claims settled (D. Del.), 526

CONTRACEPTION

Mircette, In Brief, 51
 Nuvaring, defendants barred from conducting ex parte interviews with treating MDs (E.D. Mo.), 367
 Ortho Tri-Cyclen maker challenges generic (D.N.J.), 733
 Plan B
 —Generic approved, 741
 —Ill. dispensing requirement challenged by pharmacists (Ill.), 7
 —OTC limits by FDA restrictions arbitrary (E.D.N.Y.), 334

COSOFT

Glaucoma drug, FDA exclusivity ruling upheld, 8

COST CONTAINMENT

Biogenerics examined by CBO, 16

Comparative effectiveness. *See* COMPARATIVE EFFECTIVENESS

Sebelius wants to look at all options, 440

Trends

—Generic use slows drug spending, CMS says, 42; savings over decade reported, 567; limited spending growth, 567

—Sales growth slowed in 2008, 350

COUNTERFEIT DRUGS

Criminal penalties. *See* LEGISLATION, FEDERAL, HR 1450

CRIMINAL PROSECUTION *See also* FRAUD AND ABUSE

Acquiring controlled substances by deception (W.D. Wash.), In Brief, 286

Clinical investigator may be criminally liable for not following FDA reporting requirements (5th Cir.), 175

Counterfeit drugs. *See* COUNTERFEIT DRUGS

False statements, former exec ordered to write book about case (D.D.C.), 679

Falsified drug paperwork (D.N.H.), In Brief, 617

Off-label use

—Actimmune off-label uses, indictment of CEO upheld (N.D. Cal.), 675

—Bextra marketing, ex-sales manager pleads guilty (D. Mass.), 370; sentenced, 736

—Destruction of documents, ex-manager convicted of obstruction of justice (D. Mass.), 316

“Pill mill,” pharmacist convicted (Kan. Dist. Ct.), 617

Plavix suit, former executive pleads guilty to false statements (D.D.C.), 401

Smuggling unapproved cancer drugs (C.D. Cal.), In Brief, 558

D

DATA MINING

N.H. ban on prescription data sales upheld (U.S., rev sought), 363; other states await ruling, 544

Vt. ban on sale of prescription data by MDs upheld (D. Vt.), 495; firms denied injunction, 670

DEGARELIX

Prostate cancer drug approved, 22

DELAWARE

Medicaid, Omnicare to settle overcharging claims, 638

DEPAKOTE

Epilepsy drug, FDA tells maker to pull misleading advertising, 159

Generic approved, In Brief, 164

DETROL

Bladder drug maker did not mislead PTO in prosecuting patent (D.N.J.), 461; discovery of marketing documents denied, 701

DIET DRUGS *See* WEIGHT LOSS PRODUCTS AND PROGRAMS

DIGITEK

Heart attack death blamed on heart drug (E.D. Tex.), 502

DISCOUNTS

Marketing claims settled (Pa. Commw. Ct.), 179

Medicare, gap in coverage, drug makers promise discounts for some enrollees, 744

N.Y. launches low-income drug card plan, 348

DISTRICT OF COLUMBIA

PBM disclosure law preempted (D.D.C.), 333

DORYX

Acne drug maker seeks to block generic (D. N.J.), 336

Antibiotic, generic ANDAs challenged as infringement, 14

DUAC

Acne cream maker claims infringement by generic (D. Del.), 640

DURAGESIC

Pain patch lots recalled, 46

DX-88

Hereditary angioedema drug, FDA panel favors approval, 188

E

E-HEALTH

Electronic prescriptions. *See* E-PRESCRIPTIONS

Incentives for MDs, new law studied, 322

N.M. considers requiring notification of E-health breaches, 184

E-PRESCRIPTIONS

AMA launches online learning center, 384

CalPERS plans pilot project, 348

DrFirst to offer through AMA platform, 484

Incentives sought by community pharmacists, 482

Mass. leads states for third year, 746

Medicaid, system announced in Ala., 648

Regulatory outlook 2009, 80

Usage reported, 514

EFFEXOR

Antidepressant blamed for suicide, jury verdict for drug maker upheld (7th Cir.), 230

Generics

—Challenged (D. Del.), 437

—Infringement claimed (D. Del.), 63

EFUDEZ

Dermatological drug, investment firm accused of giving trade secrets to competitor (D. Del.), 523

ELIDEL

Skin care cream blamed for cancer, suits remanded (D.N.J.), 734

ELOXATIN

Cancer drug, proposed generics no infringement (D.N.J.), 732

EMEND

Anti-nausea drug, generic plans challenged (D.N.J.), 284

EMPLOYMENT ISSUES

Merck employees class action over alleged artificially inflated stock certified (D.N.J.), 361

Overtime denied to salespersons (S.D.N.Y.), 121

ENBREL

Arthritis drug maker accused of illegal marketing (D. Mass.), 255

Non-infringement ruling affirmed (Fed. Cir.), 635

ERBITUX

Cancer drug, FDA wants additional study for first-line squamous cell carcinoma of the head and neck, 270

ERECTILE DYSFUNCTION DRUGS

Switzerland, price-fixing alleged, 214

ETODOLOC

Arthritis drug contamination blamed for death,

summary judgment granted for maker (E.D. Pa.), 708

EUROPEAN UNION (EU) *See also* specific countries

Generic drug shipments, action urged to prevent seizures, 240

Pfizer purchase of Wyeth under scrutiny, 657

R&D, EU signs off on public-private partnership projects, 628

EVISTA

Osteoporosis drug, automatic stay of generic approval upheld (Fed. Cir.), 225

TRO blocks generic (S.D. Ind.), 281; enjoined, 496

EVOCLIN

Acne foam maker seeks to block generic (D. Del.), 335

EXPERT WITNESSES

Seroquel, causation expert witness excluded (Del. Super. Ct.), 734

Zyprexa, causation expert who stretched the truth disqualified (E.D.N.Y.), 587

F

FALSE CLAIMS

Aventis to settle false price report charges, 637

BNA audioconference, In Brief, 719

Inflated prices, Mylan settles with state (D. Mass.), 40

Lipitor marketing qui tam action dismissed (E.D.N.Y.), 638

Medicaid

—Fla. pharmacy accuses drug maker of inflating prices (S.D. Fla.), 62

—Tex. amends false claims complaint against Risperdal makers (Tex. Dist. Ct.), 14

Modified liability. *See* LEGISLATION, FEDERAL, S 386

Off-label use

—Antidepressants, feds intervene in suit (D. Mass.), 226

—Lovenox qui tam suit may proceed (N.D. Ill.), 501

—Natrecor whistleblower suits, feds intervene (N.D. Cal.), 226

Public disclosure jurisdiction limited (U.S., rev grant), 729

FAMVIR

Herpes drug, infringement claim against generic maker may proceed (D.N.J.), 254; jury trial disallowed, 553

FANAPT

Schizophrenia drug approved for adults with warning, 539

FEDERAL TRADE COMMISSION (FTC)

Leibowitz as FTC chair, more scrutiny predicted for drug industry, 261

FEN-PHEN

Diet drug settlement, attorneys convicted of bilking plaintiffs (E.D. Ky.), 467

FENTORA

Pain drug, infringement claim over generic may proceed (D. Del.), 436

FLORIDA

Medicare, inhalation drug billings higher in Fla., 509

FLUCLOXACILLIN

Antibiotic associated with liver damage, 652

FLUTIROM

Asthma drug application, FDA may need more data, 691

FOCALIN XR

ADHD drug, infringement claim dismissed (D.N.J.), 95

FOOD AND DRUG ADMINISTRATION (FDA)

Appointments

—Commissioner nominee should be familiar with drug industry and have “impeccable qualifications,” health coalition says, 16; consumer groups comment, 183; President to nominate Hamburg, 317; hearings planned, 537; Hamburg approved by Senate panel, 562; approved by Senate, 589; begins work, In Brief, 620; urged to work with CMS, 646

Civil penalties, In Brief, 234

Conflicts of interest, panel member dismissed, Hinchey (D-NY) questions, 265

Enforcement increase predicted, 504

FY2010 budget

—Drug and device funding hiked, 560; deputy FDA chief testifies, 619

—Generic biotech drugs pathway included, 260

Grassley (R-Iowa) seeks clarification of employees right to discuss agency issues, 345

IT contracting criticized by HHS IG, 70

Modernization projects, GAO urges comprehensive information technology program, 647

Science, quality improvement discussed at conference, 654

Splitting FDA, Sebelius says speculation premature, 374

Transparency task force announced, 645; industry and consumer groups comment, 740

White House seeks regulatory review, 123

FORTAMET

Diabetes drug, generic ANDA challenged (D. Del.), 97

FOSAMAX

Defense attorney's trip to Australia for deposition, plaintiffs must defray costs (S.D.N.Y.), 315

Osteoporosis drug product liability, amended claim to add second drug maker permitted (S.D.N.Y.), 118

FOSRENOL

Generic, brand-name maker seeks to block generic (S.D.N.Y.), 405

Kidney disease drug maker alleges patent infringement (S.D.N.Y.), 312

FRAUD AND ABUSE

Amgen accused of illegal marketing of Enbrel and Aransep (D. Mass.), 255

BNA plans conference, In Brief, 24

Discount drug card marketing claims settled (Pa. Commw. Ct.), 179

Foreign Corrupt Practices Act compliance, Analysis & Perspective, 215

Human growth hormone imports, Colo. pharmacy settles with DOJ (D. Colo.), 13

Kickbacks. *See* ANTI-KICKBACK LAWS

Medicaid

—Ky. inflated AWP suit settled (Ky. Cir. Ct.), 311

—Mass. recoveries reported by Atty. Gen., 130

—N.C. recoveries reported for 2008, 47

—Wis., Pharmacia defrauded program through inflated prices (Wis. Cir. Ct.), 200; forfeitures sought, 556

Mishandling controlled substances, Rite Aid settles (E.D. Cal.), 97

Off-label use. *See* OFF-LABEL USE

Oxycontin misbranding, Purdue Frederick ex-execs barred from federal programs, 119

Recoveries predicted by HHS IG, 686

Viread maker accused of misrepresenting sales (N.D. Cal.), 679

FTC *See* FEDERAL TRADE COMMISSION (FTC)

G

GARDASIL

Cervical cancer vaccine broader use, FDA seeks more data, 73

GENERIC DRUGS

Affordable generics. *See* LEGISLATION, FEDERAL, S 369

ANDAs. *See* ABBREVIATED NEW DRUG

APPLICATIONS (ANDAs)

Application for Evoclin, In Brief, 324

Approvals

—Accuretic, In Brief, 298

—Alkeran, In Brief, 691

—Altace, In Brief, 298

—Biotech drugs. *See* LEGISLATION, FEDERAL, HR 1427

—CellCept, In Brief, 571

—Depakote, In Brief, 164

—Kaletra, In Brief, 324

—Keppra, In Brief, 104

—Klaron, In Brief, 386

—Lamictal, In Brief, 133

—Lithium carbonate, In Brief, 192

—Mircette, In Brief, 50; 51

—Plan B, generic approved, 741

—Precose, In Brief, 627

—Prilosec, In Brief, 134

—Restoril, In Brief, 720

—Risperdal, In Brief, 164

—Roxicodone, In Brief, 451

—Singulair, In Brief, 656

—Solodyn, In Brief, 192

—Sun Pharma, In Brief, 49

—Tegretol-XR, In Brief, 418

—Zerit, In Brief, 51

—Zithromax, In Brief, 385

Aurobindo, In Brief, 272

Authorized generics

—Ban on sales by brand-name maker, 265

—Information submission, FDA withdraws rule, 181

—Listing from FDA urged by senators, 206

—Marketing ban. *See* LEGISLATION, FEDERAL, HR 380

BCBS, community-based programs expanding use, 450

Biogenerics. *See* BIOGENERICS

Biosimilars. *See* LEGISLATION, FEDERAL, HR 1548

Biotech drugs. *See* LEGISLATION, FEDERAL, S 726

Budget for FDA includes pathway for generic biotech drugs, 260

Delaying release. *See* LEGISLATION, FEDERAL, HR 1706

Digoxin, In Brief, 418

Doryx. *See* DORYX

Duac maker claims infringement (D. Del.), 640

Effexor. *See* EFFEXOR

Efudez, investment firm accused of giving trade secrets to competitor (D. Del.), 523

Enablex, In Brief, 515

EU, action urged to prevent seizures of drug shipments, 240

Evista. *See* EVISTA

Flonaise, In Brief, 325

Imitrex, In Brief, 237

Japan, manufacturing allowed before patent expiration, 487

Lexapro, declaratory judgment against generic maker dismissed (U.S., rev den), 227

Medicaid. *See* MEDICAID

Medicare. *See* MEDICARE DRUG COVERAGE

Metoclopramide, brand name maker liable for neurological condition blamed on generic (Cal.), 117

Miacalcin, In Brief, 691

N.Y., generic use down upstate, 209

Patents

—Actonel. *See* ACTONEL

—Allegra-D maker tries to block generic (D.N.J.), 119

—Clarinet suit settled (D.N.J.), 437

—Codexis biocatalyst, In Brief, 49

—Combigan generic challenged (E.D. Tex.), 438

—Concerta, generic no infringement (D. Del.), 364

—Contan and Stalevo, infringement claims settled (D. Del.), 526

—Eloxatin, proposed generics no infringement (D.N.J.), 732

—Emend, generic plans challenged (D.N.J.), 284

—Evoclin maker seeks to block generic (D. Del.), 335

—Femcon Fe settlement (D.N.J.), In Brief, 15

—Fentora, infringement claim over generic may proceed (D. Del.), 436

—Fosrenol maker seeks to block generic (S.D.N.Y.), 405

—Mucinex D generic ANDA challenged by patent holder, 690

—Omnicef, generic created by different process no infringement (Fed. Cir.), 605

—Opana ER, infringement suit over generic dismissed (D.N.J.), 230

—Ortho Tri-Cyclen maker challenges generic (D.N.J.), 733

—Patanol, infringement alleged (S.D. Ind.), 202

—Pfizer Indian licenses announced, 624

—Prandin patent validity, summary judgment denied (E.D. Mich.), 733

—Pulmicort maker seeks to block generic (D.N.J.), 436; blocked, 461; preliminary injunction, 610

—Seroquel generic challenged (D.N.J.), 203

—Solodyn. *See* SOLODYN

—Strattera drug direct infringement claim dismissed (D.N.J.), 609

—Vanos infringement dispute settled (W.D. Mich.), 463

Paxil, supply and license contract dispute, \$70M awarded for breach (N.D. Ill.), 201

Prices lower when “authorized generics” marketed, FTC reports, 737

Prilosec, generic did not infringe (S.D.N.Y.), 309

Protonix, generic advertising challenged (E.D. Mich.), 554

Reglan blamed for movement disorder, failure-to-warn claim against generic maker not preempted (D. Vt.), 6; review denied, 465

Reverse payment deals targeted by FTC, 372

Tindamax, In Brief, 163

Topamax. *See* TOPAMAX

Tricor, consumer suit over generic delay, settlement approved (D. Del.), 500

Wellbutrin, generic makers accused of making inferior product (Cal. Super. Ct.), 706

Xeloda, generic challenged (D.N.J.), 438

Xopenex, dispute over generic settled (D. Del.), 286

Xyzal. *See* XYZAL

GENETICS AND BIOTECHNOLOGY

Biogenerics, AARP supports, 624

Biologics. *See* BIOLOGICS

Biosimilars. *See* LEGISLATION, FEDERAL, HR 1548

Data exclusivity, biotech industry seeks 14 years, 131

Generic drugs. *See* LEGISLATION, FEDERAL, S 726

Long exclusivity period pushed at conference, 622

Personalized medicine

—Key trend in biotech industry, 568

—Merck CEO urges, 566

—R&D advocates push, 538

Securities fraud class actions “differed dramatically” in 2008, survey finds, 484

GEODON

Adolescents, FDA panel backs use for mental illnesses, 715

GEORGIA

Product liability, governor proposes protection for drug and device makers, 209

GLEEVEC

Gastrointestinal cancer drug approved, 23

GRANTS

Schizophrenia drug funding, In Brief, 133

H

HEALTH AND HUMAN SERVICES

DEPARTMENT (HHS)

Comparative effectiveness panel members named, 343
Daschle pledges to improve operation of FDA and other agencies, 69; withdraws name, 156; Sebelius nominated, 263; Senate action delayed, 407; finance panel approves, 470; Senate approves, 503
FY2010 budget includes Medicaid cuts, 560; more FDA drug and device funding, 560
Stimulus funding office launched, 291

HEALTH CARE REFORM, FEDERAL

Comparative effectiveness. *See* COMPARATIVE EFFECTIVENESS

Daschle withdrawal may slow down reform efforts, 156

GOP senators drafting proposal, 711

Hatch (R-Utah) expects bipartisan bill to pass in 2009, 472

HELP panel releases draft Senate bill, 683; markup, 739

Marketing, drug firms may need to overhaul strategies, 717

Personalized medicine pushed by Merck CEO, 566

Pharmacists offer reform principles, 210

Rationing. *See* LEGISLATION, FEDERAL, S 1259

Stakeholders pledge savings, 652

HEPARIN

Adverse reaction, suit remanded to state court (S.D. Ala.), 255

Blood thinner not tied to adverse events in 3 patients, maker says, 594

Chinese firms get warning from FDA on contamination, 476

HORMONE REPLACEMENT THERAPY (HRT)

Failure-to-warn claim against maker not preempted (Tex. App.), 464

Jurisdiction lacking over ad firms with insufficient W.Va. contacts (E.D. Ark.), 367

HRT *See* HORMONE REPLACEMENT THERAPY (HRT)

HUMAN SUBJECT PROTECTION

Pfizer study subject protection program accredited, 417

HUMIRA

Arthritis drug maker alleges patent infringement (D. Mass.), 526

Patent infringement alleged (E.D. Tex.), 41; summary judgment for plaintiff denied, 585; summary judgment for defendant denied, 671

Psoriasis and arthritis drug ad broadens approved indication and minimizes risks, FDA says, 21

HYTRIN

Hypertension and prostate drug monopoly claim remanded (9th Cir.), 91

I

IBUPROFEN

Injectable dosage approved by FDA, 717

ILLINOIS

Plan B, pharmacists challenge to dispensing requirement may proceed (Ill.), 7

INDIA

Safety, FDA opens offices in India, 99

Tarcera patent infringement suit dismissed, 543

INFLUENZA

Fraudulent swine flu cures, FDA and FTC warn public, 537

Funding for Swine flu sought by White House, 534

INFORMATION NETWORKS AND TECHNOLOGY

E-health. *See* E-HEALTH

Electronic prescriptions. *See* E-PRESCRIPTIONS

Internet. *See* INTERNET

INSTITUTIONAL REVIEW BOARDS (IRBs)

Coast IRB enters voluntary agreement with FDA limiting activities, 442; shutdown, 514

INTERNATIONAL DEVELOPMENTS *See also*

specific countries

Market growth for drugs estimated for 2009, 513

UN Oil for Food Program, Danish firm settles

kickback charges (D.D.C.), 558

INTERNET

Internet pharmacies. *See* INTERNET PHARMACIES

Risk information lacking from many Internet ads, 413

State developments

—Pa. price database launched, 293

—Wyo. drug database access bill signed, 321

Ultram ER web video called misleading by FDA, 623

INTERNET PHARMACIES

N.J. Assembly approves regulation, 321

IOWA

Physician gifts, Senate approves ban, 349

IPLEX

ALS patients to have access, 288

IRBs (INSTITUTIONAL REVIEW BOARDS)

Coast IRB enters voluntary agreement with FDA limiting activities, 442

J

JAPAN

Generic manufacturing allowed before patent expiration, 487

JURISDICTION

AndroGel, class actions seek to recoup charges paid due to collusion between brand name and generic firms, transferred to Ga. federal court (C.D. Cal.), 435

Blood factor concentrates, Taiwanese hemophiliacs suits may proceed in Cal. (N.D. Ill.), 96

Elidel suits remanded (D.N.J.), 734

Heparin adverse reaction, suit remanded to state court (S.D. Ala.), 255

Lipitor infringement suit stayed over jurisdiction issues (N.D. Ill.), 703

Reglan liability suit properly removed to federal court (E.D. Pa.), 529

Risperdal, jurisdiction lacking to hear patent counterclaims (U.S., rev den), 340

K

KALETRA

AIDS drug, price cut in Mexico, 387

KENTUCKY

Medicaid, inflated AWP suit settled (Ky. Cir. Ct.), 311

KETEK

Antibiotic, concealment of hazards alleged, depositions blocked (E.D.N.Y.), 557

KICKBACKS *See* ANTI-KICKBACK LAWS

L

LABELS AND PACKAGING *See also* SAFETY; WARNINGS

Acetadote, In Brief, 26

Asthma drug makers asked by FDA to add precaution on adverse events, 718

Epilepsy drug suicide risk, FDA approves warning labels, 532

Evolence, In Brief, 691

Libel, packaging product criticized in journal, suit dismissed (S.D. Ind.), 405

Metoclopramide must add box warning on risks of long-term or high-dose use, 269

Pegintron, In Brief, 325

Preemption of state laws, White House seeks review of rules, 618

Rebetol, In Brief, 325

Testosterone gel to get box warning, 565

Toll-free number on medication guides, FDA issues guidance, 351

Vyvanse, In Brief, 656

LEGISLATION, FEDERAL

Ed. Note: This heading covers bills with assigned numbers. For information on measures not yet assigned numbers, see specific subject headings.

HR

—**1**, American Recovery and Reinvestment Act, includes comparative effectiveness research, 126; House approves, 180; signed, 205; industry cautiously optimistic, 241

—**380**, Authorized generic drugs marketing ban, Emerson (R-Mo), 99

—**684**, Medicare Prescription Drug Savings and Choice Act, Berry (D-Ark), would create drug plan under traditional program, 125

—**759**, Food and Drug Administration Globalization Act, would require international parity in inspections, expand FDA powers, 128

—**1260**, Patent Reform Act, Conyers (D-Mich), would create first-to-file system, 262; House urged to conform bill to S 515, 535

—**1427**, Promoting Innovation and Access to Life-Saving Medicine Act, Waxman (D-Cal), Pallone (D-NJ), Deal (R-Ga), Emerson (R-Mo), would allow FDA to approve generic versions of expensive biotech drugs, 287; pressure high to pass, 472

—**1450**, Counterfeit Drug Prevention Act, Rogers (R-Mich), would create criminal penalties, 319

—**1548**, Pathway for Biosimilars Act, Eshoo (D-Cal), Inslee (D-Wash), Barton (R-Tex), would create regulatory path at FDA, 318; Johnson & Johnson supports, 407; New Democrat Coalition supports, 508; Eshoo wants quick action, 590

—**1706**, Protecting Consumer Access to Generic Drugs, would bar brand-name firms from pay for delays, FTC chief supports, 371; House panel approves, 642; hearing held, 642

—**1859**, Independent Drug Education and Outreach Act, Waxman (D-Cal), Pallone (D-NJ), would create academic detailing program to provide MDs with unbiased drug information, S 767 is companion, 374

SConRes

—**13**, FY2010 budget resolution, Kyl (R-Ariz) amendment on research-based delays rejected, 409

S

—**1**, American Recovery and Reinvestment Act, includes comparative effectiveness research, 126; Senate approves, 180

—**301**, Physician Payment Sunshine Act, Kohl (D-Wis) and Grassley (R-Iowa), would require firms to report payments and gifts to MDs, 127

—**369**, Preserve Access to Affordable Generics Act, Kohl (D-Wis) and Grassley (R-Iowa), would ban makers from paying firms to keep generics off market, 155; FTC says ban would produce savings, 738

LEGISLATION, FEDERAL —Contd.

§ —Contd.

- 386**, Fraud Enforcement and Recovery Act (FERA) of 2009, expands False Claims Act liability, signed, 619
- 501**, Fair Prescription Competition Act, Rockefeller (D-WVa), would bar sale of authorized generics by brand-name maker, 265
- 515**, Patent Reform Act, Leahy (D-Vt) and Hatch (R-Utah), would create first-to-file system, 262; Senate action delayed, 344; compromise possible soon, 375; compromise approved, 408; HR 1260 is counterpart, 535; panel report, 563
- 610**, Patent Reform Act, Kyl (R-Ariz), would rewrite provisions concerning conditions for patentability, 344
- 726**, Promoting Innovation and Access to Life-Saving Medicine Act, Brown (D-Ohio), Schumer (D-NY), Collins (R-Maine), Martinez (R-Fla), Stabenow (D-Mich), Vitter (R-La), would allow FDA to approve generic version of biotech drugs, 372
- 767**, Independent Drug Education and Outreach Act, Kohl (D-Wis), Kennedy (D-Mass), Durbin (D-Ill), would create academic detailing program to provide MDs with unbiased drug information, HR 1859 is companion, 374
- 882**, Drug and Device Accountability Act, Kennedy (D-Mass) and Grassley (R-Iowa), would increase FDA resources to inspect drugs, 507
- 1110**, Medicare Payment Advisory Commission (MedPAC) Reform Act, Rockefeller (D-WVa), would create executive branch agency, 620
- 1259**, Preserving Access to Targeted, Individualized, and Effective New Treatments, Kyl (R-Ariz) and McConnell (R-Ky), seeks to prevent rationing, 711
- 1859**, Independent Drug Education and Outreach Act, Kohl (D-Wis), Kennedy (D-Mass), Durbin (D-Ill), would create academic detailing program to provide MDs with unbiased drug information, 374

LETAIRIS

Hypertension drug, FDA alleges misleading comments by maker, 295

LEVAQUIN

Antibiotic patent term extension approved (D.N.J.), 607
Discovery costs denied in patent dispute (Fed. Cir.), 702

LEXAPRO

Antidepressant approved for adolescents, 350
Competing patents, two claims invalidated by prior art (S.D.N.Y.), 673
Declaratory judgment against generic maker dismissed (U.S., rev den), 227
Destruction of electronic records alleged (E.D. Mich.), 462

LIPITOR

Cholesterol drug infringement suit stayed over jurisdiction issues (N.D. Ill.), 703
Marketing qui tam action dismissed (E.D.N.Y.), 638
Technical fix on patent, In Brief, 50

LIRAGLUTIDE

Diabetes drug cancer risk disputed, 414

LOTREL

Hypertension drug, low-dose ANDA challenged as infringement (D.N.J.), 13; dismissed, 201

LOVENOX

Anticoagulant off-label use, qui tam suit may proceed (N.D. Ill.), 501
Blood clot drug patent not enforceable (U.S., rev sought), 171; (rev den), 495

LUMIZYME

Pompe disease treatment, FDA seeks more information, 270

M

MARKETING *See also* ADVERTISING; CONFLICTS OF INTEREST

Academic detailing program. *See* LEGISLATION, FEDERAL, HR 1859, S 767
Aplenzin, In Brief, 24
Authorized generics marketing ban. *See* LEGISLATION, FEDERAL, HR 380
Cefazolin, In Brief, 191
Centany, In Brief, 516
Cholesterol drug makers accused of deceptive promotion (E.D. Pa.), 678
Discount drug card marketing claims settled (Pa. Commw. Ct.), 179
Emsam, In Brief, 656
Epiduo Gel, In Brief, 50
Exactacain, In Brief, 272
Gelnique launch, In Brief, 627
Health care reform, drug firms may need to overhaul strategies, 717
J&J fined over misleading materials for MDs (W.Va. Cir. Ct.), 283
Kapindex, In Brief, 238
Keppra XR, In Brief, 451
Letairis, FDA alleges misleading comments by maker, 295
Megace maker target of DOJ, 381
Moxatag, In Brief, 49
Naprelan, In Brief, 78
NTC-801, In Brief, 298
Off-label promotion and use. *See* OFF-LABEL USE
Overtime for drug firm sales reps, guidance sought from Cal. court (9th Cir.), 555
Oxycodone, In Brief, 486
Prices. *See* PRICING
Rapaflo, In Brief, 418
Rispedal, In Brief, 656
Savella, In Brief, 298; 486
State developments
—Mass., licensing of drug and device agents, Senate bill amended, 688; dropped from budget, 743
—Vermont
—Gift ban for drug firms, expansion approved, 592; signed, 688
—Spending by drug firms reported, 474
Timoptic, In Brief, 237
Toviaz, In Brief, 655
Uloric, In Brief, 325
Unapproved drugs. *See* SAFETY
Uramaxin, In Brief, 516
Vaprisol, In Brief, 384
Vyvanse, In Brief, 385
Zometa not withdrawn for safety or effectiveness reasons, FDA says, 448

MASSACHUSETTS

Conflicts of interest
—Fees for covered firms due Jul. 1, 648
—Gifts to MDs, limits criticized, 71; conferences moved from Boston, 129; creates controversy, 158; final rules adopted, 292
—Hospital network to limit interaction with industry, 441
E-prescriptions, Mass. leads states for third year, 746
False claims, inflated prices, Mylan settles with state (D. Mass.), 40
Licensing of drug and device agents, Senate bill amended, 688; dropped from budget, 743
Medicaid
—Pricing suit against drug maker, nationwide settlement does not bar suit (D. Mass.), 311
—Recoveries reported by Atty. Gen., 130

MAXIPIME

Antibiotic, no higher mortality risk reported by FDA, 716

MEDICAID

Alabama
—E-prescribing system announced in Ala., 648
—Pricing suits
—5 firms settle with state over pricing (Ala. Cir. Ct.), 40
—Jury awards \$78.4M against drug maker (Ala. Cir. Ct.), 227
—More firms settle (Ala. Cir. Ct.), 610
California
—Medi-Cal cuts challenged by pharmacists (C.D. Cal.), 151; cuts enjoined, 256; hospital and pharmacy reimbursement cuts blocked (9th Cir.), 404
Del., Omnicare to settle overcharging claims, 638
Drug reimbursement rule delayed (D.D.C.), 228
Fraud. *See* FRAUD AND ABUSE
FY2010 budget includes cuts, 560
Generic drugs
—Payment revisions urged, 538
—Reimbursement gap with Medicare reported by HHS IG finds, 268
Mass. pricing suit against drug maker, nationwide settlement does not bar (D. Mass.), 311
PhRMA and Families USA unveil expansion campaign, 485
Protonix overcharges alleged (D. Mass.), 582
Rebate hike considered in Senate, 589
Regulatory outlook 2009, 80
Wash. pharmacy reimbursement cuts blocked (W.D. Wash.), 403; agency to reexamine cuts, 592; agency to cut reimbursements, 621

MEDICARE DRUG COVERAGE

Ed. Note: Entries at this heading refer to Medicare Part D unless otherwise indicated.
Accessibility to drugs increased by program, 76
Adjusting reimbursements, HHS IG finds potential savings, 508
Biologics use limited, 412
Compendia, conflicts of interest seen as inherent, 625
Executive agency status for MedPAC. *See* LEGISLATION, FEDERAL, S 1110
Gap in coverage, drug makers promise discounts for some enrollees, 744
Generic drugs
—Biotech drugs pushed, savings predicted, 320
—Reimbursement gap with Medicaid, HHS IG reports, 268
Industry ties to MDs, MedPAC reports, 266
Inhalation drug billings higher in Fla., 509
Negotiated prices
—Cost sharing rule issued by CMS, 42
—Opposed by ex-CMS chief, 207
Off-label use
—Conditions for coverage more complex for drugs than devices, 382
—Ovarian cancer treatment, contractor to cover, 471
—State Atty. Gen. support CMS proposal to block insurers' requirement, 345
Outpatient drug spending reported, 412
Oversight a challenge for HHS, 43
Pharmacogenomic testing of anticoagulants covered only for clinical trials, CMS proposes, 531
Prices. *See* PRICING
Protected drug classes. CMS issues rule, 100; manage care group opposes expansion, 346
Roche bids for Genentech, 162
Traditional program. *See* LEGISLATION, FEDERAL, HR 684
Utilization management data, CMS urges plan sponsors to outline of websites, 376

MEGACE

Eating disorder drug marketing, maker target of DOJ, 381

MERGERS AND ACQUISITIONS

Alprostadil, In Brief, 163
Astellas wants CV Therapeutics, In Brief, 134; bid rejected, 238; offer dropped, In Brief, 324
Cephalon
—Arana, In Brief, 272
—Ception, In Brief, 105
CVS Caremark merger, FTC probe sought, 565; pharmacists group alleges monopoly, 565
Degarelix, In Brief, 271
Endo and Indevus, In Brief, 50; 352
Express Scripts to buy WellPoint PBMs, 448; community pharmacists oppose, 512
Gilead to buy CV Therapeutics, 323
GSK
—Genelabs, In Brief, 49
—Stiefel, In Brief, 486
Helsinn and Sapphire, In Brief, 133
J&J
—Cougar purchase planned, 624; FTC clears, 748
—Omrix purchase, In Brief, 51
LFA-1 inhibitor, In Brief, 298
Lundbeck and Ovation, In Brief, 191
Merck to buy Schering-Plough, 295; effect on innovation, FTC urged to examine, 449
Novartis generic injectibles business, In Brief, 627
Pfizer
—Insulin factory, In Brief, 297
—Wyeth purchase, 131; FTC wants more data, 418; effect on innovation, FTC urged to examine, 449; under EU scrutiny, 657
Pharmexa and Affitech, 271
Piramal and Minrad, In Brief, 24
PPD buys vaccine testing lab, 48
Roche
—Genentech purchase planned, 296; tender offer, In Brief, 385
—Memory, In Brief, 51
Sanofi purchase of Zentivz, EU agencies require spinoffs, 214
Takeda to buy IDM Pharma, In Brief, 595
Teva, Barr purchase cleared by FTC, 23
Watson and Arrow, In Brief, 719
Wyeth buys Thiakis, In Brief, 25
Zevalin, In Brief, 238

METOCLOPRAMIDE

Brand name maker liable for neurological condition blamed on generic (Cal.), 117
Failure to warn claims
—Fla., preempted (W.D. Fla.), 231
—Ky., preempted (W.D. Ky.), 231
Gastrointestinal drug makers must add box warning on risks of long-term or high-dose use, 269
Heartburn drug blamed for neurological injuries (MDL), 708

MEXICO

Kaletra price cut, 387

MICHIGAN

Immunity for drug firms, House approves repeal, 378

MINNESOTA

Gifts to MDs, bill to ban withdrawn, 378
Psychiatric clinical trial limits, bill signed, 593

MINOCIN

Anti-bacterial drug, failure-to-warn claim not preempted (N.D. Ill.), 364

MIRAPEX

Restless leg drug blamed for compulsive gambling (D. Minn.), 341

MUCINEX D

Pseudoephedrine HCl, generic ANDA challenged by patent holder, 690

MULTAQ

Irregular heartbeat drug, FDA panel favors approval, 350

N

NANOTECHNOLOGY

Collaboration announced by FDA, 291

NAPRELAN

Anti-inflammatory drug infringement suit dismissed (S.D. Fla.), 284

NATRECOR

Heart drug off-label use, feds intervene (N.D. Cal.), 226

NEO-SYNEPHRINE

Nasal decongestant addiction, suit time-barred (N.D. Ill.), 177

NEUROTONIN

Epilepsy drug, causation evidence permitted in suicide suit over off-label use (D. Mass.), 556; class certification denied, 612
Patient class decertified in off-label use suit (Pa. Ct. Com. Pl.), 258
Widow of suicide victim sues, off-label use alleged (D. Minn.), 588

NEW HAMPSHIRE

Data mining, ban on prescription data sales upheld (U.S., rev sought), 363; other states await ruling, 544
Privacy, shredding of health records, requirement considered, 184

NEW JERSEY

Internet pharmacies regulation, Assembly approves, 321

NEW MEXICO

Privacy, state considers requiring notification of E-health breaches, 184

NEW YORK

Budget includes lower drug costs and bans industry gifts to MDs, 20; signed, 444
Discounts, low-income drug card plan launched, 348
Generic use down upstate, 209
Pharmacy chains agree to free language services, 474

NEXIUM

Heartburn drug, false advertising class action remanded (3rd Cir.), 587

NIFEDIPINE

Generic hypertension drug, direct purchasers antitrust class action certified (D.C. Cir.), 229

NIGERIA

Trovan settlement, hearing planned on claim that Pfizer tried to circumvent victims' attorneys (Conn. Super. Ct.), 616

NORTH CAROLINA

Medicaid fraud recoveries reported for 2008, 47

NUVARING

Contraceptive product liability, defendants barred from conducting ex parte interviews with treating MDs (E.D. Mo.), 367

O

OFF-LABEL USE

Actimmune. *See* ACTIMMUNE
Aranesp class action dismissed (C.D. Cal.), 730
Bextra marketing, ex-sales manager pleads guilty (D. Mass.), 370; sentenced, 736

Destruction of documents, ex-manager convicted of obstruction of justice (D. Mass.), 316
Enforcement, increased scrutiny predicted, Special Report, 420
False claims. *See* FALSE CLAIMS
Guidance on promotion offered by legal experts, 745
Lovenox qui tam suit may proceed (N.D. Ill.), 501
Medicare
—Coverage conditions more complex for drugs than devices, 382
—State Attys. Gen. support CMS proposal to block insurers' requirement, 345
Neurotonin patient class decertified (Pa. Ct. Com. Pl.), 258
Pediatric products, Special Report, 572
Regulatory outlook 2009, 80
"Reprint practices," FDA issues guidance, 65
RICO does not apply to off-label promotion of approved drugs (C.D. Cal.), 37
Zyprexa marketing. *See* ZYPREXA

OMNICEF

Antibiotic, generic created by different process no infringement (Fed. Cir.), 605

ONGLYZA

Diabetes drug, FDA panel favors approval, 414; application, timeline extended, 513

OPANA ER

Painkiller, patent infringement suit over generic dismissed (D.N.J.), 230

ORGAN TRANSPLANTS

TOL101, In Brief, 451

ORPHAN DRUGS

DNage BV, In Brief, 515
Grant program planned by FDA for clinical trials, 18
HPN-100, In Brief, 18; designation received, 541
Oxycyte, In Brief, 571
Paclical, In Brief, 451
Qutenza, In Brief, 656
RiaSTAP approved for bleeding in patients with congenital fibrinogen deficiency, 102; approved, In Brief, 299
TOL101, In Brief, 451

ORTHO TRI-CYCLEN

Contraceptive maker challenges generic (D.N.J.), 733

OVCON

Chewable contraceptive formulation, antitrust settlement reached (D.D.C.), 12

OXYCONTIN

Misbranding, Purdue Frederick ex-execs barred from federal programs, 119

P

PATADAY

Allergy eye ANDA, infringement claimed (S.D. Ind.), 63
Eyedrop ANDA, infringement alleged (S.D. Ind.), 202

PATANOL

Eye treatment generic, infringement alleged (S.D. Ind.), 202

PATENTS

Acular patent upheld (U.S., rev den), 117
ADX-N05, In Brief, 570
Antidepressant competing patents, two claims invalidated by prior art (S.D.N.Y.), 673
Azopt maker alleges infringement (E.D. Tex.), 119
BiTE antibody, In Brief, 77
BNA plans audioconference, In Brief, 190
Brazil, pipeline law challenged, 597
Cabilly II, PTO confirms claims of validity, 270

PATENTS—Contd.

Carvedilol, infringement claim settled (D.N.J.), 587
Cephem compound double patent challenge, summary judgment vacated (Fed. Cir.), 433
Cipro settlement challenged (U.S., rev den), 730
Clarinox patent suit settled (D.N.J.), 437
Clobel patent infringement alleged (N.D. Tex.), 63
Detrol maker did not mislead PTO in prosecuting patent (D.N.J.), 461
Enbrel, non-infringement ruling affirmed (Fed. Cir.), 635
Focalin, infringement claim dismissed (D.N.J.), 95
Fosrenol maker alleges infringement (S.D.N.Y.), 312
High priority changes urged at PTO, In Brief, 19
Humira. *See* HUMIRA
“Imminent importation” of allegedly infringing drugs, revised opinion issued (Fed. Cir.), 524
Levaquin. *See* LEVAQUIN
Lexapro. *See* LEXAPRO
Licensing
—Antibody license, In Brief, 192
—Aricept licensing, In Brief, 299
—Assay licensing, In Brief, 77
—AV513 license, In Brief, 25
—Axomadol licensing, In Brief, 272
—Blinatumomab licensing, In Brief, 324
—Caerulomycin A license, In Brief, 238
—Campath, Genzyme buys rights, 384
—CDA-1 and CDB-2 license, In Brief, 486
—Cimzia licensing, In Brief, 191
—Depression drugs licensing, In Brief, 191
—DI-Leu16-IL2 license, In Brief, 323
—DOTPA chloride license, In Brief, 238
—Elinogrel rights, In Brief, 213
—Heart drug licenses, In Brief, 627
—IDX889 licensing, In Brief, 191
—JAK2 inhibitors licensed to Onyx, 48
—Lupuzar license, In Brief, 163
—Pain drug licensing, In Brief, 191
—Reloxin license, In Brief, 450
—Tetrabenazine licensing, In Brief, 595
—UCB drug rights, In Brief, 77
—VIA licenses, In Brief, 24
—Wellbutrin, U.S. rights purchased, In Brief, 540
—Zevalin licensing, In Brief, 78
Lipitor. *See* LIPITOR
Lovenox patent not enforceable (U.S., rev sought), 171; (rev den), 495
Messenger protein, patent invalid for lack of adequate written description (Fed. Cir.), 399
Milestone payments, In Brief, 77
Naprelan infringement suit dismissed (S.D. Fla.), 284
Oforta, In Brief, 570
Pataday. *See* PATADAY
Prosecution process, PTO may issue rules changing (Fed. Cir.), 337; rehearing sought, 669
Reform
—Conditions for patentability. *See* LEGISLATION, FEDERAL, S 610
—Congress urged to scale back controversial proposals, 186
—CRS publishes analysis, 128
—First-to-file. *See* LEGISLATION, FEDERAL, HR 1260, S 515
—Urged at PTO, 43
Reversing patent settlements, Analysis & Perspective, 749
Risk evaluation and mitigation strategy patents, Analysis & Perspective, 28
Rythmol SR patent dispute settled (D. Del.), 463
Skelaxin method patents invalid (E.D.N.Y.), 92
Tarcera infringement suit dismissed in India, 543
Truvada V drug ANDA infringes patent (S.D.N.Y.), 10

PAXIL

Antidepressant product liability settlement approved (D.P.R.), 282
Generic, supply and license contract dispute, \$70M awarded for breach (N.D. Ill.), 201

PBM *See* PHARMACY BENEFITS MANAGEMENT (PBM)

PENNSYLVANIA

Price database launched, 293

PHARMACISTS AND PHARMACIES

CVS accused of failing to protect patient data (FTC), 199; pharmacists seek probe, 351
Electronic prescriptions. *See* E-PRESCRIPTIONS
N.Y. chains agree to free language services, 474
“Pill mill,” pharmacist convicted (Kan. Dist. Ct.), In Brief, 617
Plan B, pharmacists challenge to Ill. contraceptive dispensing requirement may proceed (Ill.), 7
Tenn., disclosing drug cost information, bill passed, 621
Wal-Mart settles recordkeeping charges, 46

PHARMACY BENEFITS MANAGEMENT (PBM)

Antitrust, Internet pharmacy denied access to PBM networks, claim time-barred (5th Cir.), 527
D.C. PBM disclosure law preempted (D.D.C.), 333
Express Scripts to buy WellPoint PBMs, 448

PHENERGAN

Anti-nausea drug “IV push” blamed for gangrene and loss of guitar player’s arm, failure to warn claim not preempted (U.S.), 249; Analysis & Perspective, 353; preemption limits, Analysis & Perspective, 388; discussed at conference, 564; effect on preemption defense, Analysis & Perspective, 658

PHYSICIANS

Conflicts of interest
—AstraZeneca to disclose payment to health care professionals who speak on its behalf, 623
—Codes of conduct urged by industry group, 236
—Gifts. *See* Gifts, *this heading*
—Harvard Medical School to revise policy, 161
—Increased disclosure sought by IOM, 511
—Industry ties to MDs, MedPAC reports, 266
—Medical students, promotional items may influence unconscious attitudes, 569
—Pfizer to disclose payments to health care professionals for consulting, speaking engagements, clinical trials, 189
—Professional medical associations urged to reject industry funding, 380
—Stanford med school to post MD-industry ties, 416
Gifts
—Conn. ban urged, 293
—Federal reporting bill. *See* LEGISLATION, FEDERAL, S 301
—Iowa Senate approves ban, 349
—Mass. limits criticized, 71; conferences moved from Boston, 129; creates controversy, 158; final rules adopted, 292
—Minn. bill to ban withdrawn, 378
—N.Y. budget proposal includes industry gift ban, 20
—Sunshine act, passages in 2009 predicted, 289
Pondimin, prescribing MD is not seller entitled to indemnity from maker (Tex. App. Ct.), 641

PLAVIX

Antiplatelet drug, less effective in some patients, FDA reports, 133
Antitrust, former executive pleads guilty to false statements (D.D.C.), 401
Independence Blue Cross placement of Plavix in highest tier upheld (E.D. Pa.), 707

POLYHEME

Red blood cell substitute, maker shuts down, 594

PONDIMIN

Diet drug, prescribing MD is not seller entitled to indemnity from maker (Tex. App. Ct.), 641

PRANDIN

Diabetes drug patent validity, summary judgment denied (E.D. Mich.), 733

PRASUGREL

Antiplatelet drug, FDA panel favors approval, 159; consumer group opposes, 649

PRICING

Ala. pharmacies suit over reimbursement, summary judgment denied (M.D. Ala.), 312
Average wholesale price, Wis. Atty. Gen. settles with drug firms (Wis. Cir. Ct.), 11
Brand name prices up in 2008, 481
Brazil authorized price hikes, 387
Cal. counties denied class certification in suit against drug firms (N.D. Cal.), 611
Erectile dysfunction drugs, price-fixing alleged in Switzerland, 214
Kaletra, price cut in Mexico, 387
Medicaid. *See* MEDICAID
Medicare Part B, changes to save money urged by HHS IG, 17
Pa. price database launched, 293
RICO suit brought by third-party payer over prices, settlement approved (D. Mass.), 307; appeal planned, 500; challenged, 553

PRIOLOSEC

Food poisoning, maker accused of failure to warn (S.D. Ohio), 680
Impax generic infringed valid patent (U.S., rev sought), 147; (rev den), 282
Ulcer drug, generic did not infringe (S.D.N.Y.), 309

PRIVACY AND CONFIDENTIALITY

CVS accused of failing to protect patient data (FTC), 199; pharmacists seek probe, 351
De-identified health information and state regulation, Analysis & Perspective, 422
State developments
—N.H. considers requiring shredding of health records, 184
—N.M. considers requiring notification of E-health breaches, 184
—Trends, more states consider limits on health data marketing, 184
—Va. considers requiring notification of health data breaches, 184

PRODUCT LIABILITY

Accutane blamed for inflammatory bowel disease, new trial ordered (N.J. Super. Ct.), 313
Aldara blamed for severe skin symptoms, claim time-barred (D. Utah), 257
Avandia failure-to-warn suits remanded (E.D. Pa.), 284
Blood factor concentrates, Taiwanese hemophiliacs suits may proceed in Cal. (N.D. Ill.), 96
Chantix wrongful death suit, breach of warranty claim may proceed (S.D. Ind.), 178
Digitek blamed for heart attack death (E.D. Tex.), 502
Effexor blamed for suicide, jury verdict for drug maker upheld (7th Cir.), 230
Elidel suits remanded (D.N.J.), 734
Etodolac contamination blamed for death, summary judgment granted for maker (E.D. Pa.), 708
Federal preemption in drug and device suits, Analysis & Perspective, 106
Fosamax. *See* FOSAMAX
Heparin adverse reaction, suit remanded to state court (S.D. Ala.), 255
HRT. *See* HORMONE REPLACEMENT THERAPY (HRT)
Injection devices, injuries blamed on continuous use (C.D. Cal.), 528
Ketek, concealment of hazards alleged, depositions blocked (E.D.N.Y.), 557
Legal outlook 2009, 79

PRODUCT LIABILITY —Contd.

Methamphetamine costs incurred by government entities, ephedrine and pseudoephedrine makers not liable (8th Cir.), 39
Metoclopramide. *See* METOCLOPRAMIDE
Minocin, failure-to-warn claim not preempted (N.D. Ill.), 364
Neo-Synephrine addiction, suit time-barred (N.D. Ill.), 177
Neurotonin. *See* NEUROTONIN
Nuvaring, defendants barred from conducting ex parte interviews with treating MDs (E.D. Mo.), 367
Outlook 2009, 135
Paxil settlement approved (D.P.R.), 282
Phenergan blamed for gangrene and loss of guitar player's arm, failure to warn claim not preempted (U.S.), 249; Analysis & Perspective, 353; preemption limits, Analysis & Perspective, 388; discussed at conference, 564; effect on preemption defense, Analysis & Perspective, 658
Pondimin, prescribing MD is not seller entitled to indemnity from maker (Tex. App. Ct.), 641
Prilosec, maker accused of failure to warn of food poisoning risk (S.D. Ohio), 680
Redux, FDA approval preempts failure-to-warn claim (N.D. Ohio), 366
Reglan. *See* REGLAN
Remicide, blamed for pulmonary fibrosis, key expert excluded (11th Cir.), 203
Seroquel. *See* SEROQUEL
State developments
—Ga. governor proposes protection for drug and device makers, 209
—Mich. House approves repeal of immunity for drug firms, 378
Ulcer drug recall, plaintiff had no side effects denied, claim dismissed (N.D. Cal.), 529
Vioxx consumer class action, certification denied (N.J. Super. Ct.), 340
Vytorin misrepresentation claims, makers submit FDA evaluation on effectiveness (D.N.J.), 176
Zyprexa. *See* ZYPREXA

PROPOXYPHENE

Pain drug risks, FDA panel recommends taking off market, 155

PROPYLTHIOUACIL

Hyperthyroidism drug, liver risk cited, 646

PROTONIX

Acid suppressant drugs, Medicaid overcharges alleged (D. Mass.), 582
Erosive esophagitis treatment, motion to enjoin generic denied (Fed. Cir.), 585
Gastroesophageal reflux drug, generic advertising challenged (E.D. Mich.), 554

PROVENGE

Prostate drug, politically-motivated delay in approval alleged, dismissal affirmed (U.S., rev den), 61

PULMICORT

Asthma drug maker seeks to block generic (D.N.J.), 436; blocked, 461; preliminary injunction, 610

PURCHASING POOLS

Savings for group purchasing organizations reported, 539

R

RACKETEER INFLUENCED AND CORRUPT ORGANIZATIONS (RICO) ACT

Off-label promotion of approved drugs, RICO does not apply (C.D. Cal.), 37
Third-party payer suit over prices, settlement approved (D. Mass.), 307; appeal planned, 500; challenged, 553

RAPTIVA

Psoriasis drug adverse events, FDA issues advisory, 233
Pulled from market, link to fatal nervous system disorder cited, 413

REDUX

Diet drug, FDA approval preempts failure to warn claim (N.D. Ohio), 366

REGLAN

Gastrointestinal reflux drug blamed for movement disorder, failure-to-warn claim against generic maker not preempted (D. Vt.), 6; review denied, 465
Jurisdiction, liability suit properly removed to federal court (E.D. Pa.), 529
Neurological movement disorder blamed on drug, failure-to-warn claim not preempted (W.D. Okla.), 310
Tardive dyskinesia blamed on generic drug, brand-name maker not liable (W.D. Ark.), 614

REIMPORTATION

Billings, Mont., importer held in contempt (Mont. Dist. Ct.), 154
Dorgan (D-ND) and Snowe (R-Me) expect bipartisan bill to pass, 68
Good importer practices, agencies issue guidance, 66
Regulatory outlook 2009, 80
Safe importation bill offered in Senate, 264

REMICIDE

Arthritis drug blamed for pulmonary fibrosis, key expert excluded (11th Cir.), 203
Distribution agreement, arbitration sought, 622

REPORTING REQUIREMENTS

Clinical trials
—Investigator may be criminally liable for not following FDA reporting requirements (5th Cir.), 175
—Registries use up, reporting requirements of journals and agencies cited, 410
Electronic filing of drug data, FDA issues guidance, 645
Physician gifts. *See* LEGISLATION, FEDERAL, S 301

RESEARCH AND DEVELOPMENT (R&D)

Antibiotics, In Brief, 386
Antibodies, In Brief, 386
ARX424, In Brief, 237
Cancer. *See* CANCER
Cetorelix pamoate, In Brief, 298
Combination drugs. *See* COMBINATION DRUGS
Contract research groups, BNA plan audioconference, 297
Cordex and Cato BioVentures, In Brief, 238
Debio 0928, In Brief, 748
Diabetes drugs in development, 594
DXL625, In Brief, 271
Elesclomol, In Brief, 720
Endo and Alexa, In Brief, 164
EU signs off on public-private partnership projects, 628
ExonHit collaborating with Allergan, 47
FASgen and Centocor, In Brief, 50
Funding reported for 2008, 297
Genyous, In Brief, 164
Huntington's drugs, In Brief, 515
IC14, In Brief, 570
ImQuest and Arisyn, In Brief, 515
Influenza drug development, FDA drafts guidance, 233
Malaria, In Brief, 485
Merck and Cardiome, In Brief, 451
MS treatment, In Brief, 77; 77
Nanotechnology collaboration announced by FDA, 291
Neurological disease drugs, In Brief, 450
Ophthalmic conditions, In Brief, 516
Personalized medicine pushed by R&D advocates, 538

Pimavanserin tartrate, 541
Riquent, In Brief, 50
STP-206, 418
Therapeutic peptides research increasing, 654
Tuberculosis, In Brief, 720
UDB, In Brief, 25
Udenafil, In Brief, 50
Wyeth to collaborate with Pharma, In Brief, 77

RESTANZA

Pneumonia, drug called safe, but not effective by FDA panel, 649

RIASTAP

Orphan drug approved for bleeding in patients with congenital fibrinogen deficiency, 102; approval, In Brief, 299

RICO *See* RACKETEER INFLUENCED AND CORRUPT ORGANIZATIONS (RICO) ACT

RISPERDAL

Application, In Brief, 213
Bipolar disorder, In Brief, 595
Generic
—Approved, In Brief, 164
—Jurisdiction lacking to hear patent counterclaims (U.S., rev den), 340
—Marketed, In Brief, 656
Schizophrenia drug, Tex Atty. Gen. amends Medicaid false claims complaint (Tex. Dist. Ct.), 14

RIVAROXABAN

Anti-clotting drug gets favorable review from FDA panel, 351; gets complete response letter, 650

ROCEPHIN

Infection treatment, FDA revises prescription information, 447

RYTHMOL SR

Heart drug patent dispute settled (D. Del.), 463

S

SABRIL

Epilepsy drug cleared by FDA panel, 73

SAFETY

Actavis manufacturing, FDA seeks to bar drugmaking at N.J. facility (D.N.J.), 61
ADHD drugs tied to cardiac deaths, FDA reports, 714
Asthma drugs and suicidal behavior, FDA continues review, 74
Biologics plant shutdown, 718
Botox, FDA announces new safety measures, 534
CellCept, FDA requires medication guide with prescriptions, 210
Cold products may affect sense of smell, FDA says, 718
Consumer risk-benefit information, simplification sought, 267
Digoxin recall, In Brief, 385
Duragesic pain patch lots recalled, 46
Ethex recall expanded, In Brief, 163
Flucloxacillin associated with liver damage, 652
Foreign drugs
—Globalization raises issues for FDA, 506
—India, FDA opens offices, 99
—Parity in inspections. *See* LEGISLATION, FEDERAL, HR 759
—Pilot safety program launched by FDA, 99
Heparin not tied to adverse events in 3 patients, maker says, 594
Insulin pen sharing, In Brief, 377
KV stops tablet shipments, 22; suspends manufacturing and shipping of all products, 132; agrees to manufacturing injunction (E.D. Mo.), 251
Liraglutide cancer risk disputed, 414
Macroboid recall, In Brief, 541

SAFETY —Contd.

Maxipime, no higher mortality risk reported by FDA, 716
Medicated patches and MRIs, FDA issues warning, 289
Methadone use, In Brief, 510
Opioids, FDA will require risk evaluation and mitigation strategies, 182; pushed by stakeholders, 644
Oversight
—Communicating risk, panel offers advice for FDA, 532
—Foreign drugs. *See* Foreign drugs, *this heading*
—Increased FDA inspection resources. *See* LEGISLATION, FEDERAL, S 882
—Legal outlook 2009, 79
—More resources urged for FDA, 102
—Proprietary drug names, FDA issues review information software, 206
—Regulatory outlook 2009, 80
—Sentinel Initiative at FDA, Senators want updates, 69
Propafenone HCl recall, In Brief, 352
Propoxyphene, FDA panel recommends taking off market, 155
Propylthiouacil, liver risk cited, 646
Ranbaxy plant, FDA says data falsified, 235
Raptiva. *See* RAPTIVA
Rocephin, FDA revises prescription information, 447
Sentinel Initiative, FDA plans to open docket, 533
Seroquel, concerns raised over new indications, 269
Simponi and fungal infections, FDA warns providers, 651
Skin-numbing products, FDA issues advisory on side effects, 98
Supply chain safety, FDA drafts guidance, 98
Toll-free number on medication guides, FDA issues guidance, 351
Transdermal patches recalled, 351
Treanda patients, skin reaction reported, 513
Tysabri, In Brief, 486
Ultram ER lots recalled, 47
Unapproved drugs
—Narcotics, FDA warns firms to stop making and selling, 381; Lannett to continue marketing, 414; allowed for dying patients, 441
—Permanent injunction placed on Advent, 447
—Smuggling unapproved cancer drugs (C.D. Cal.), In Brief, 558
Vytorin, safety reviewed by FDA, 73
Wash., tamper-resistant prescription pad bill signed, 593
Weight loss supplement ingredients, FDA alerts consumers, 18
Xigris, FDA probes bleeding events and deaths, 160
Zonegran may cause metabolic acidosis, FDA report, 236

SECURITIES

Adolor shareholder derivative suit dismissed (E.D. Pa.), 615
Alzheimer's drug, securities fraud class action dismissed (S.D.N.Y.), 369
Biotechs, fraud class actions "differed dramatically" in 2008, survey finds, 484
Blood clot drug misstatements, securities fraud class action dismissed (N.D. Cal.), 12
Celebrex, investors suit over alleged clinical study misrepresentations timely (3rd Cir.), 150
Cosmetics firm accused of channel stuffing and failure to disclose acne drug problems (N.D. Cal.), 615
Derivative suit plaintiffs did not show futility of making pre-suit demand on Pfizer board (2nd Cir.), 120
Disclosure process and SEC filings, advice offered to firms, 479
Gilead accused of material misstatements about demand for Viread (U.S., rev den), 464
Merck workers stock drop claim may proceed (D.N.J.), 368

Prostate drug, investors accuse maker of false statements (S.D.N.Y.), 259
Vioxx maker accused of misrepresenting safety profile and commercial viability (U.S., rev grant), 608
Viread maker accused of misrepresenting sales (N.D. Cal.), 679

SERDOLECT

Schizophrenia drug, FDA panel favors approval for certain patient populations, 415

SEROQUEL

Adolescents, FDA panel backs use for mental illnesses, 715
Antipsychotic diabetes suits
—Causation, expert witness excluded (Del. Super. Ct.), 734
—Documents indicate maker suppressed negative trial results and downplayed diabetes risk (M.D. Fla.), 252; evidence of foreign actions excluded, 314
—Summary judgment granted for maker (M.D. Fla.), 152
Generic challenged (D.N.J.), 203
Safety
—FDA panel says drug not safe for all patients, 446
—New indications raise safety concerns, 269

SILENOR

Insomnia drug rejected by FDA, 446

SIMPONI

Approved for arthritis, 513
Fungal infections, FDA warns providers, 651

SINGULAIR

Asthma drug and suicidal behavior, FDA continues review, 74

SKELAXIN

Muscle relaxant method patents invalid (E.D.N.Y.), 92

SOLODYN

Acne drug generic patent dispute settled (D. Del.), 337
Proposed generic, infringement alleged (D. Del.), 705

STALEVO

Parkinson's drug infringement claims settled (D. Del.), 526

STATUTES OF LIMITATIONS

Neo-Synephrine addiction, suit time-barred (N.D. Ill.), 177
Taiwanese hemophiliacs claims against blood concentrate makers time-barred (N.D. Ill.), 466

STEM CELL RESEARCH

ALS trial, In Brief, 26
License agreement, In Brief, 541
Osiris and FDA, In Brief, 104

STRATTERA

ADHD drug direct infringement claim dismissed (D.N.J.), 609

SUPREME COURT, U.S.

Antidepressants, failure-to-warn of suicide risk, preemption ruling remanded (dec), 280
False Claims Act public disclosure jurisdiction limited (rev grant), 729
Generic drugs
—Lexapro, declaratory judgment against generic maker dismissed (rev den), 227
—Prilosec, generic infringed valid patent (U.S., rev sought), 147; (rev den), 282
—Risperdal, jurisdiction lacking to hear patent counterclaims (rev den), 340
N.H. ban on prescription data sales upheld (rev sought), 363; other states await ruling, 544
Patents
—Acular patent upheld (rev den), 117

—Cipro settlement challenged (rev den), 730
—Generic drugs. *See* Generic drugs, *this heading*
—Lovenox patent not enforceable (rev sought), 171; (rev den), 495
Phenergan blamed for gangrene and loss of guitar player's arm, failure to warn claim not preempted (dec), 249; Analysis & Perspective, 388; preemption limits, Analysis & Perspective, 388; discussed at conference, 564; effect on preemption defense, Analysis & Perspective, 658
Provenge, politically-motivated delay in approval alleged, dismissal affirmed (rev den), 61
Securities, Gilead accused of material misstatements about demand for Viread (rev den), 464
Vioxx maker accused of misrepresenting safety profile and commercial viability (rev grant), 608

SURFAXIN

Respiratory distress syndrome drug application, FDA wants more data, 477

SWINE FLU OUTBREAK

Emergency use of flu drugs approved by FDA, 507

SWITZERLAND

Erectile dysfunction drugs, price-fixing alleged, 214

T

TARCECA

Cancer drug patent infringement suit dismissed in India, 543

TENNESSEE

Disclosing drug cost information, bill passed, 621

TEXAS

Medicaid, false claims complaint against Risperdal makers amended (Tex. Dist. Ct.), 14

TOPAMAX

Anticonvulsant, generic exclusivity awarded by FDA, 469
Seizure drug, generic, In Brief, 385; approved, In Brief, 415

TREANDA

Lymphoma drug, skin reaction reported, 513

TRICOR

Anti-cholesterol drug, consumer suit over generic delay, settlement approved (D. Del.), 500

TROVAN

Antibiotic clinical trials, maker accused of violating international norms (2nd Cir.), 147
Nigerian settlement, hearing planned on claim that Pfizer tried to circumvent victims' attorneys (Conn. Super. Ct.), 616

TRUVADA

HIV drug ANDA infringes patent (S.D.N.Y.), 10

U

ULTRAM ER

Pain drug lots recalled, 47
Web video called misleading by FDA, 623

V

VACCINES

Cervarix, In Brief, 385
Gardasil broader use, FDA seeks more data, 73
PPD buys vaccine testing lab, 48
Recombivax HB, In Brief, 50

VANOS

Skin cream infringement dispute settled (W.D. Mich.), 463

VASOVIST INJECTION

Contrast imaging agent approved, 23

VELCADE

Cancer drug maker accused of overstating efficacy, 746

VERMONT

Data mining, ban on sale of prescription data by MDs upheld (D. Vt.), 495; firms denied injunction, 670

Gift ban for drug firms, expansion approved, 592; signed, 688

Marketing, spending by drug firms reported, 474

VIOXX

Consumer class actions

—Cal., certification denied (Cal. Super. Ct.), 586

—N.J., certification denied (N.J. Super. Ct.), 340

Securities fraud, maker accused of misrepresenting safety profile and commercial viability (Fed. Cir.), 608

VIREAD

Antiretroviral drug maker accused of misrepresenting sales (N.D. Cal.), 679

Gilead accused of material misstatements about demand (U.S., rev den), 464

VIRGINIA

Privacy, state considers requiring notification of health data breaches, 184

VYTORIN

Cholesterol drug clinical trials, Waxman (D-Cal) and Stupak (D-Mich) seek more information, 233

Misrepresentation claims, makers submit FDA evaluation on effectiveness (D.N.J.), 176

Safety reviewed by FDA, 73

VYVANSE

ADHD drug exclusivity decision challenged (D.D.C.), 253; proceedings stayed, 434

W**WARNINGS**

Fanapt approved for adult schizophrenia with warning, 539

Over-the-counter drugs, In Brief, 510

Raptiva adverse events, FDA issues advisory, 233

WASHINGTON

Medicaid pharmacy reimbursement cuts blocked (W.D. Wash.), 403; agency to reexamine cuts, 592;

agency to cut reimbursements, 621

Tamper-resistant prescription pad bill signed, 593

WEIGHT LOSS PRODUCTS AND PROGRAMS

Combination drug blamed for death (E.D. Pa.), 438

Fen-phen settlement, attorneys convicted of bilking plaintiffs (E.D. Ky.), 467

Redux, FDA approval preempts failure-to-warn claim (N.D. Ohio), 366

WELLBUTRIN

Antidepressant, direct purchaser antitrust suit may proceed (E.D. Pa.), 308

Generic makers accused of making inferior product (Cal. Super. Ct.), 706

U.S. rights purchased, In Brief, 540

WISCONSIN

Average wholesale price, Atty. Gen. settles with drug firms (Wis. Cir. Ct.), 11

Medicaid, Pharmacia defrauded program through inflated prices (Wis. Cir. Ct.), 200; forfeitures sought, 556

WOMEN'S HEALTH

HRT. *See* HORMONE REPLACEMENT THERAPY (HRT)

WYOMING

Internet, drug database access bill signed, 321

X**XELODA**

Cancer drug, generic challenged (D.N.J.), 438

XIGRIS

Sepsis drug, FDA probes bleeding events and deaths, 160

XOPENEX

Asthma drug, dispute over generic settled (D. Del.), 286

XYZAL

Antihistamine maker challenges generic (E.D.N.C.), 733

Application for generic, In Brief, 747

Y**YAZ**

Contraceptive maker to submit TV ads to FDA, 189

Z**ZOMETA**

Bone-building drug not withdrawn for safety or effectiveness reasons, FDA says, 448

ZONEGRAN

Epilepsy drug may cause metabolic acidosis, FDA report, 236

ZYPREXA

Adolescents, FDA panel backs use for mental illnesses, 715

Antipsychotic drug overpayments, class certification for third party payers granted (2nd Cir.), 152

Causation expert who stretched the truth disqualified (E.D.N.Y.), 587

Off-label uses, Lilly settles with Justice Dep't (E.D. Pa.), 93

Suicide blamed on drug, verdict for maker upheld (5th Cir.), 402

Warnings would not have changed usage, summary judgment for maker (E.D.N.Y.), 677